The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Domestic business was up 41.9% YoY and 27.7% QoQ
The hospital works in close collaboration with the Network for Organ Sharing and the National Organ & Tissue Transplant Organisation (NOTTO) and it is amongst the very few hospitals doing ABO-incompatible transplant
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
Subscribe To Our Newsletter & Stay Updated
